Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

decitabine

Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.

BIOLOGICAL

DC/AML fusion cells

An investigational agent that tries to help the immune system to recognize and fight against cancer cells

Trial Locations (2)

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER